SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

RIZZI, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.134
AS - Asia 4.033
EU - Europa 2.899
SA - Sud America 605
AF - Africa 62
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 17.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.961
SG - Singapore 1.672
CN - Cina 1.244
DE - Germania 821
UA - Ucraina 511
BR - Brasile 505
GB - Regno Unito 356
IT - Italia 339
HK - Hong Kong 334
FI - Finlandia 330
TR - Turchia 315
VN - Vietnam 214
RU - Federazione Russa 132
SE - Svezia 110
CA - Canada 95
FR - Francia 67
IN - India 67
MX - Messico 60
PL - Polonia 58
JP - Giappone 43
BE - Belgio 38
AR - Argentina 32
BD - Bangladesh 31
NL - Olanda 31
ZA - Sudafrica 30
ES - Italia 29
LT - Lituania 26
ID - Indonesia 19
EC - Ecuador 18
IQ - Iraq 16
CZ - Repubblica Ceca 15
CO - Colombia 12
AE - Emirati Arabi Uniti 11
PK - Pakistan 11
UZ - Uzbekistan 11
SA - Arabia Saudita 10
MA - Marocco 9
PY - Paraguay 8
TN - Tunisia 8
VE - Venezuela 8
CL - Cile 7
IR - Iran 7
UY - Uruguay 7
AT - Austria 6
IL - Israele 6
NP - Nepal 6
PE - Perù 6
DO - Repubblica Dominicana 5
BG - Bulgaria 4
GR - Grecia 4
IE - Irlanda 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CH - Svizzera 3
EG - Egitto 3
HR - Croazia 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
KR - Corea 3
NO - Norvegia 3
SN - Senegal 3
AL - Albania 2
AU - Australia 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
LB - Libano 2
NZ - Nuova Zelanda 2
PA - Panama 2
SV - El Salvador 2
AM - Armenia 1
AZ - Azerbaigian 1
CG - Congo 1
CR - Costa Rica 1
CV - Capo Verde 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
NE - Niger 1
NI - Nicaragua 1
TT - Trinidad e Tobago 1
Totale 17.740
Salva come PNG Salva come JPEG
Città #
Fairfield 1.156
Woodbridge 1.108
Ashburn 1.041
Singapore 1.026
Houston 670
Jacksonville 576
Ann Arbor 564
Chandler 513
Seattle 442
Beijing 424
Wilmington 411
Santa Clara 403
Cambridge 379
Munich 340
Hong Kong 331
Izmir 185
Los Angeles 165
Nanjing 154
New York 146
Helsinki 145
Dallas 131
Milan 118
Princeton 113
San Diego 101
Boardman 100
Shanghai 88
Turku 72
Ho Chi Minh City 71
São Paulo 66
Ferrara 61
Nanchang 60
Dearborn 54
London 48
Warsaw 48
Hanoi 47
Shenyang 47
Tokyo 42
Brussels 37
Mexico City 37
Frankfurt am Main 35
Hebei 35
Orem 35
Bremen 34
Denver 33
Falkenstein 33
Brooklyn 32
Tianjin 30
Buffalo 29
Hefei 29
Auburn Hills 25
Chicago 25
Atlanta 24
Jiaxing 24
Mountain View 24
San Mateo 24
Montreal 23
Falls Church 22
Johannesburg 22
Mcallen 22
Toronto 22
Norwalk 21
Rio de Janeiro 20
Boston 19
Changsha 19
Chennai 18
Stockholm 18
Bologna 17
Jinan 17
Montréal 17
Moscow 17
Philadelphia 17
Phoenix 17
Zhengzhou 17
Addison 16
Poplar 16
San Francisco 16
The Dalles 16
Manchester 15
Mumbai 15
Redwood City 15
Kunming 14
Tappahannock 13
Indiana 12
Belo Horizonte 11
Ningbo 10
Tashkent 10
Washington 10
Bexley 9
Biên Hòa 9
Charlotte 9
Columbus 9
Dhaka 9
Guangzhou 9
Olomouc 9
Wroclaw 9
Ankara 8
Guayaquil 8
Orange 8
Padova 8
Querétaro 8
Totale 12.637
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 346
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 275
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 252
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 241
A new selective antagonist of the nociceptin receptor 235
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 234
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 222
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 219
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 219
A new ligand for the urotensin II receptor 218
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 216
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 211
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 211
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 205
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 205
Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies 203
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120 194
Effects of vasoactive agents in healthy and diseased human saphenous veins 194
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 192
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 191
Ala scan analogues of HOE 140. Synthesis and biological activities 190
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 189
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 189
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 188
Pharmacological characterization of tachykinin tetrabranched derivatives 188
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 187
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 186
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 185
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 185
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 183
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 181
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 179
Pharmacological characterization of nociceptin receptor: an in vitro study 179
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 178
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 177
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 176
Pharmacological characterisation of novel kinin B2 receptor ligands 175
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 175
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 175
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 174
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 173
B1 and B2 kinin receptors in various species 172
Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity 172
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 170
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 169
Structure-activity study at positions 3 and 4 of human neuropeptide S. 168
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 168
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 166
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 166
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 165
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 165
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 165
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 164
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 163
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 158
Anxiolytic-like effect of neuropeptide S in the rat defensive burying 158
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 157
Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR 190997: An in vitro study on human, rabbit and pig vascular B2 receptors 156
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 154
Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors) 153
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 152
Characterization of the human vascular kinin B2 receptor by binding assays. 152
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 150
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 148
Structure-activity relationship study on human urotensin II 148
Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A 147
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist 147
Characterization of endothelin receptors in the human umbilical artery and vein 145
Nociceptin/orphanin FQ receptor ligands 144
The mouse vas deferens: A pharmacological preparation sensitive to nociceptin 143
Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure activity relationships 142
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 141
Pharmacology of the Kallikrein-Kinin system 141
Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys 141
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor 138
Receptors for kinins in the human isolated umbilical vein 137
In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol 137
In vitro pharmacological profile of peptide III-BTD: A novel ligand for nociceptin/orphanin FQ and opioid receptors 136
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor 136
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist 135
Pharmacology of nociceptin and its receptor: a novel therapeutic target 134
Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery 131
In vitro characterization of FR 190997, the first non peptide B2 receptor agonist receptor binding and bioassay in the human umbilical vein 130
Effects of Ro 64-6198 it nociceptin/orphanin FQ-sensitive isolated tissues 130
Endogenous nociceptin signaling and stress-induced analgesia 128
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor 128
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors 127
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study 125
Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities 123
Receptor binding profile of novel nociceptin/orphanin FQ receptor ligands in mouse brain membranes 122
Pharmacology of [tyr1]nociceptin analogs: receptor binding and bioassay studies 119
Receptor binding profile of novel nociceptin/orphanin FQ receptor ligands in mouse brain membranes. 118
Further studies on nociceptin/orphanin FQ related peptides: discovery of a new chemical template with antagonist activity on the OP4 receptor. 115
Further studies on nociceptin related peptides: discovery of new molecules with antagonist activity on the nociceptin receptor 114
Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad? 111
null 110
null 105
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative 105
Pharmacological characterization of the nociceptin receptors in the mouse: receptor binding, bioassay and behavioral studies 103
MEN 11270, a novel selective constrained peptide antagonist with high affinity at the human B-2 kinin receptor 96
Totale 16.638
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.714
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.714
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021842 0 0 0 0 0 160 46 178 31 171 188 68
2021/20221.209 45 117 98 81 65 48 64 80 50 104 112 345
2022/20231.252 119 58 58 162 211 169 97 106 162 5 61 44
2023/2024646 73 82 30 16 35 131 24 57 9 12 21 156
2024/20252.838 67 70 209 108 326 315 126 171 418 239 430 359
2025/20264.253 849 329 619 1.013 1.132 311 0 0 0 0 0 0
Totale 17.840